H Lundbeck A/S (LUN.CO) stock: key figures, P/E, revenue and dividend
Denmark · ISIN DK0010287234
H Lundbeck A/S financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 22.00 bn DKK | 24.35 bn DKK |
| Gross profit | 17.77 bn DKK | 19.38 bn DKK |
| EBIT | 3.27 bn DKK | 6.34 bn DKK |
| Net income | 3.14 bn DKK | 3.19 bn DKK |
Full history since 1995, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About H Lundbeck A/S
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
More stocks
- EDGEWELL PERSONAL CARE Co (EPC)
- RPC INC (RES)
- MEDICAL PROPERTIES TRUST INC (MPT)
- Fsilon Furnishing and Construction Materials Corp (605318.SS)
- GREENBRIER COMPANIES INC (GBX)
- Seojin System Co.Ltd (178320.KQ)
- Hagerty, Inc. (HGTY)
- Leon's Furniture Limited (LNF.TO)
- Tong Hsing Electronic Industries Ltd (6271.TW)
- Lotus Pharmaceutical Co Ltd (1795.TW)
- Ruffer Investment Company Ltd (RICA.L)
- Norion Bank AB (NORION.ST)
Not investment advice. All data without warranty, price as of 12.09.2026. Details in the risk notice.